DexCom, Inc. (DXCM)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 4,662,000,000 15.6%
- Net income
- 836,300,000 45.1%
- Gross profit
- 2,801,900,000
- Operating income
- 911,800,000
- Earnings per share
- 2.14 46.6%
- R&D expense
- 599,100,000
Growth and profitability
- Gross margin
- 60.10
- Operating margin
- 19.56
- Net margin
- 17.94
- Return on equity
- 30.46
- Return on assets
- 13.19
- Free cash flow margin
- 23.11
Balance sheet
- Total assets
- 6,339,900,000
- Total liabilities
- 3,593,900,000
- Shareholders' equity
- 2,746,000,000
- Cash and equivalents
- 917,700,000
- Current ratio
- 1.88
Cash flow and ratios
- Operating cash flow
- 1,440,700,000
- Free cash flow
- 1,077,200,000
Shareholder returns
- Share buybacks
- 500,000,000
- Shares outstanding
- 372,950,922
- Book value per share
- 7.36
Company information
- Headquarters
- San Diego, CA
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Surgical & Medical Instruments & Apparatus
Fiscal year end: · Source: SEC EDGAR
DexCom, Inc. trades on NASDAQ under the ticker symbol DXCM. This page brings together its price chart, company profile, key financial figures and technical indicators.